Phaseline

Companies › Shanghai AB PharmaTech

Shanghai AB PharmaTech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Nov 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ABP1011T–Phase 2SCLC, Extensive StageNov 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07321574ABP1011TPhase 2SCLC, Extensive StageOncologyNov 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.